Tag Archives: JPM

Compelling New Technology Startups Selected RESI@JPM Innovation Challenge

29 Dec

By Dennis Ford, Founder & CEO, LSN

The 11th Redefining Early Stage Investments (RESI) Conference will be joining the JPM fray for our largest event yet on January 10th in San Francisco. We’re excited to announce the early stage life science companies that will be participating in the RESI Innovation Challenge.

The 30 participating companies have been hand-selected by LSN’s scientific review committee based on the innovative nature of their core technology and how well-positioned each is to capitalize on their respective market opportunities.

Therapeutics
 
Digital Health
 

Diagnostics
 

Medtech Devices
 

Heading to JPM? Read The RESI SF Agenda

29 Sep

By Dennis Ford, Founder & CEO, LSN

dennis-websit

Biotech and medtech industry executives are already drawing up their itineraries for January’s healthcare conference week in San Francisco. It’s on track to be a busy week for us all. Among the many events and receptions taking place, the Redefining Early Stage Investments Conference (RESI SF) stands alone in providing a targeted opportunity for early stage biotech and medtech companies to schedule up to 16 face-to-face investor meetings in one venue, with the potential for many more ad-hoc investor discussions throughout the day.

Partnering is RESI’s core, but at RESI SF also provides a full day of investor panels and workshops devoted to early stage life science investment topics. We’ll see the return of the RESI Asia-North America track, with content for entrepreneurs who are looking to the Asia Pacific region as a source of investment or future customers. RESI will also feature sessions focused on investors in each main life science technology vertical, and on key investor categories including Family Offices, Angels and Big Pharma, and a new session on Tech Giants in Healthcare.

With a full day of content and meetings, we’re on course for another sellout San Francisco RESI event. Don’t leave it too late to get your ticket.

agendawp

162801425610010374

Preparing for JPM? It’s Time to Apply to the RESI Innovation Challenge

22 Sep

By Dr. William Kohlbrenner, CSO, LSN

bill-1010-2wpWith summer now behind us, the world’s biotech and medtech community is counting down to the San Francisco healthcare conference season. If you’re making your JPM plans now, it’s definitely time to apply to the RESI Innovation Challenge.

LSN’s scientific team is preparing to review the RESI Innovation Challenge applications from biotech, medtech, diagnostic and healthcare IT companies.  Successful applicants will be provided with an all-day display space for their startup company at RESI – and with the heavy foot traffic at JPM, there’s never been a better opportunity to win investor exposure for your new technology. All applicants are vetted by LSN’s scientific review team, with a view to not just the quality of the company’s scientific work, but also the strength of the management team and how well-positioned the company is to receive investment.

On January 10th, all RESI attendees will have the opportunity to vote on the 30 Innovation Challenge finalists.  See below for the past winners – a diverse group of startups from every area of the life sciences.

What makes the RESI Innovation Challenge so valuable?  We’ve included a few words from previously successful participants below, but in short, being part of the Innovation Challenge provides startups with a new way to get attention and start dialogues with the investors who attend RESI. Participants can share their message all day in the exhibit hall, with their Innovation Challenge display providing a starting point for a meaningful conversation about the opportunity.

Here is what our previous winners are saying about the RESI Innovation Challenge:

DSC00392

“It was an absolute pleasure to participate in the RESI conference held at MaRS in Toronto. The unique structure of the conference facilitated creating new relationships with potential investors and partners. In particular, the Innovation Challenge pushed us to introduce ourselves to new people, which will be useful as we look towards a future financing round. I definitely recommend the RESI conferences to entrepreneurs seeking financing in the bio / health space.”
 
– Raymond Shih, President, Co-Founder, QoC Health
3rd Place, RESI on MaRS, June 23, 2016

“I love the RESI Innovation Challenge because it is a great way to give our pitch to practice it and try to obtain a scarce resource from these investors. Practicing with these investors is a great way to build relationships and continue that on to the real investment conversations.”

– Niko Skievaski, Co-Founder, Redox

1st Place, RESI@TMCx, June 8, 2015

02

“The RESI Innovation Challenge is a really good opportunity to meet investors and other companies in the space.  It’s a good showcase to reach that audience.”

– Jessica Ching, CEO, Eve Medical

2nd Place, RESI San Francisco, January 12, 2016

“The RESI Innovation Challenge is a unique way to pitch, and provides a great opportunity to see what other companies are doing in the industry, while allowing you to meet with potential investors and strategic partners outside of the partnering meetings.”

– John Connolly, VP Corporate Development, Rna Diagnostics

1st Place, RESI Boston, September 16, 2015

01

“RESI offers small companies like GeneSegues a direct line to potential partners and potential investors in a small setting conducive to relationship building and conversation. The Innovation Challenge was a particularly great way to introduce our company to a broader audience than I could meet with personally which allowed us to leverage the showcasing of our technology more efficiently.”

-Laura M. Brod,Chief Executive Officer,GeneSegues Therapeutics

-1st Place, RESI @TMCx, April 11, 2016

Previous RESI Innovation Challenge 1st place winners include:

237521341025992000

You’ll be redirected to the application page. Please fill out this form as completely as possible. The application process takes approximately 15 minutes. If it will take you more than 30 minutes to fill out the form, please download the application form here: https://goo.gl/09TuE9 and send it to resi@lifesciencenation.com. Note: There is no fee to apply.

RESI@JPM: Biotech Angels Discuss Where and How They Fit into a Fundraise

25 Feb

By Cole Bunn, Research Analyst, LSN

cole-wp

Life science angel investors have long been a fundamental piece of a fundraising campaign, typically providing strategic guidance and capital to entrepreneurs who are right out of the gate. Relaxed crowdfunding provisions and big pharma’s increased involvement in early-stage companies, among other developments, has created new opportunities for angels to find, fund and exit biotech companies. This crucial investor class speaks to the types of deals they like to do, what it’s like to work with an angel investor and how they see the biotech and investment landscapes evolving.

To hear directly from the investors, watch the RESI video recap here:

RESI@JPM Innovation Challenge – Winners Announced

21 Jan

By Nono Hu, Director of Marketing, LSN

Last week, LSN’s Redefining Early Stage Investments (RESI) Conference brought together approximately 350 early stage investors and 300 biotech, medtech and healthcare IT entrepreneurs, our largest crowd to date. The RESI Innovation Challenge received a record number of applicants last fall. The 30 most innovative applicants were hand selected by Life Science Nation’s internal scientific review board and presented their technologies in an exhibition-style format throughout the full-day conference. Here are the top 3 winners!

First Prize Winner: ClearSight

01

ClearSight LLC is commercializing a novel intraocular lens (IOL), the ClearSight IOL, designed to prevent clouding of the lens known as posterior capsular opacification (PCO). PCO is the most frequent surgical complications from cataract surgery, occurring in 25% of patients and costing the U.S. healthcare system $350 million/year. Animal data demonstrates that the ClearSight IOL reduces PCO by 100% in a rabbit model, due to the patent-protected ClearSight IOL design and the addition of a novel microscopic surface texture to prevent cell migration that leads to clouding of the lens. IOLs represent a $1.1 billion U.S. market and $3.7 billion global market.

02

George Ayd, Assistant Vice President, MedMarc; Shravanthi Reddy, COO, ClearSight

 

Second Prize Winner: Eve Medical

03Eve Medical is a Toronto-based medical device company dedicated to improving women’s health. Eve’s core product HerSwab™ makes it easy for women to collect their own samples at home or in clinic to test for common infections that cause cervical cancer, pelvic inflammatory disease and infertility. This saves time, provides privacy and minimizes invasiveness. By reduce barriers to screening, and improving compliance, Eve Medical and HerSwab™ can empower under-served women, improve the reach of existing programs, increase test volumes, and reduce costs for healthcare systems.

04

Michael Quigley, VP of Market Research, LSN; Jessica Ching, CEO, Eve Medical; Dennis Ford, CEO, LSN

 

Third Prize Winner: Briteseed

05The surgeon’s lack of tactile feedback during minimally invasive laparoscopic and robotic surgery leads to difficulty in safely visualizing and manipulating blood vessels, ureters, and bile ducts. Briteseed combats this problem by building smart surgical tools using low-cost optical technology to non-invasively visualize both between and near the jaws of a surgical tool in real time. This combination hardware and software solution is flexible enough to be seamlessly integrated into a spectrum of surgical tools. These smart tools will provide imaging and diagnostic capabilities without interrupting surgical workflow, increasing user adoption. By raising the quality and decreasing overall cost of care, Briteseed provides value to surgeons and the hospital administrations that support them.

06

Michael Quigley, VP of Market Research, LSN; Mayank Vijay, Head of BD and Operations & Co-founder, Briteseed

 

RESI@JPM – The Good News, And The Bad News

7 Jan

By Dennis Ford, Founder & CEO, LSN

dennis-websit

With LSN’s Redefining Early Stage Investments (RESI) conference coming up next Tuesday, I am delighted to announce the good news is RESI seems to have caught fire in the early stage global investor community, with investors making up half of the registered attendees.

The bad news is, when you add that to the fundraising CEOs, RESI Innovation Challenge participants, exhibitors and sponsors, we’ve reached capacity at our venue. We’re therefore unable to take any more registrations.

However, here’s the program guide; we hope that if you didn’t make it to RESI@JPM, you will be able to join us at one of our three events later this year in Houston (April 11th), Toronto (June 23rd), or Boston (September 13th). If you’d like to attend a future RESI event, plan early!

 

Early Stage Global Investors Converging on RESI@JPM

5 Nov

By Dennis Ford, Founder & CEO, LSN 

dennis-websit

JPM week is a very busy time of year for the biotech and medtech industries. With investors’ January schedules already filling up, it’s important for entrepreneurs to get themselves in the right place at the right time in order to meet with the hundreds of investors who will be in San Francisco that week. That is how you create relationships that could lead to an allocation.

LSN’s Redefining Early Stage Investments San Francisco event will be taking place on January 12th, 2016, and is shaping up to be the most dynamic yet in terms of investors already signing up. Evidently, investors are more organized than the rest of us! I am pleased to announce that RESI already has 150 investors from 16 countries registered to attend the event. This early trend is on track to surpass our most recent events in Boston and at TMCx in Houston in terms of investor turnout.

If you’d like to see all the firms and funds that have already registered for RESI, click the image below. We’re excited to welcome these and many more investors to the greatest RESI yet. If you’d like to join us at RESI, register here.

WP-list-